Cure TV

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves survival in platinum-resistant ovarian cancer.

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care.

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

During Kidney Cancer Awareness Month, Dr. Eric Singer shares warning signs, risk factors and when younger adults should speak with a doctor about kidney health.

Dr. Kevin Kalinsky discusses common side effects associated with the FDA-approved combination of Enhertu and Perjeta for breast cancer.

Fifteen-year follow-up from the S0016 trial found over one-third of patients with follicular lymphoma treated with chemoimmunotherapy had no progression.

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for patients with TNBC.

Dr. Eric Singer reveals the latest advances in kidney cancer care that help patients live longer and maintain quality of life.

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, discussed how the standard of care for melanoma is evolving.

Survivor Julie Cohen discusses her experience with cevostamab, managing CRS side effects, and reaching MRD-negative status through a clinical trial.

Keytruda/Welireg and Welireg/Lenvima combinations show improved survival and disease control in kidney cancer, according to new data from ASCO GU.

Day two of ASCO GU highlighted innovative therapies and the need for better quality-of-life reporting in genitourinary cancer trials.

Dr. Eric Singer discusses rising early-onset kidney cancer, the role of hereditary syndromes like VHL, and lifestyle tips for patients under age 50.

Dr. Ranee Mehra shares guidance on recurrence, quality-of-life concerns and clinical trials for patients with head and neck cancers and caregivers.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future, as Dr. Sagar Lonial explained.

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions.

Lauren Yerkes shares how her breast cancer diagnosis uncovered generations of genetic information for her family.

In a trial of 171 women, app-based self-acupressure improved fatigue vs usual care, offering a low-cost option for ovarian cancer survivors.

In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.

Cancer-related fatigue may persist despite improved sleep or treated depression, underscoring it as a distinct and complex symptom.

Dr. William Audeh discusses how genomic subtyping can close the 38% mortality gap for Black women by identifying aggressive basal-type cancers.

Dr. Rodney Haring discusses strategies to reduce cancer mortality among Native Americans through patient navigation, clinical trials and tribal sovereignty.

Dr. Alex Francoeur of UC Irvine urges patients with ovarian cancer to ask questions, seek second opinions and build trusted relationships with oncologists.

A study led by Dr. J. William Harbour of UT Southwestern Medical Center marks a shift in how doctors predict the spread of uveal melanoma.

Heather Quintana Suchan shares how work and music community support her while she lives fully with stage 4 lung cancer.

Dr. Shaun P. McKenzie discusses bile duct cancer challenges and why awareness and specialized care help patients get diagnosed earlier and live longer.